Introduction

Liposarcoma is a malignant tumour of fat tissue and a common soft tissue sarcoma in adults. Diagnosing it can be difficult, especially in distinguishing well-differentiated liposarcoma from benign lipomas, because they look very similar. This is where molecular markers like MDM2 and CDK4 help. These markers are usually found in liposarcoma, but not in lipomas. These markers enhance diagnostic accuracy and help to guide appropriate treatment.

Overview of liposarcoma subtypes

There are different types of liposarcoma, and each behaves differently. Knowing the subtype helps guide treatment.  

• Well-differentiated liposarcoma (WDL): Benign lipomas are low-grade tumours but have potential for local recurrence. For accurate diagnosis, the amplification of MDM2 and CDK4 genes is useful, which makes molecular testing essential
• De-differentiated liposarcoma (DDL): A more aggressive form that evolves from WDL(well-differentiated lymphosarcoma), characterised by a transition to high-grade non-lipogenic sarcoma. Like WDL, to support its identification, it typically exhibits MDM2 and CDK4 amplification
• Myxoid/round cell liposarcoma: Composed of uniform round cells in a myxoid stroma, this subtype has a distinctive FUS-DDIT3 gene fusion. It lacks MDM2/CDK4 amplification, making other genetic tests more useful here
• Pleomorphic liposarcoma: The rarest and most aggressive type, marked by pleomorphic cells and complex genetic abnormalities. MDM2 and CDK4 are generally not amplified, making diagnosis reliant on histology and other markers

Testing for these gene changes (called molecular profiling) helps doctors tell liposarcoma apart from benign adipocytic tumours and in subclassifying types, which influences treatment planning and prognosis.

Molecular pathogenesis of liposarcoma

Liposarcoma develops due to specific changes in its genetic material. One key change involves a part of chromosome 12 (called 12q13-15), which is particularly seen in well-differentiated and dedifferentiated liposarcomas.

This region contains important oncogenes, notably:

• MDM2, which inhibits the tumour suppressor p53, allowing cells to evade apoptosis
• CDK4, which promotes cell cycle progression by inactivating the retinoblastoma (Rb) protein

These amplifications can cause uncontrolled cell growth and survival and play a central role in liposarcoma oncogenesis. Detection of these alterations aids in accurate diagnosis and differentiation from benign lipomatous tumours.

MDM2: structure and function

MDM2 (Murine Double Minute 2) is an oncogene located on chromosome 12q15. MDM2 encodes a protein that negatively regulates the p53 tumour suppressor pathway by promoting p53 degradation, which helps to control survival and cell growth. 

In well-differentiated and dedifferentiated liposarcomas, MDM2 is often overexpressed due to gene amplification. The activity suppression of p53 allows cells to evade apoptosis and to continue proliferating unchecked.

MDM2 amplification is common in liposarcoma but rare in benign lipomas. To differentiate liposarcoma from benign adipocytic tumours, the detection techniques are immunohistochemistry or FISH, which offer high sensitivity and specificity, making it a valuable tool in diagnosing.

CDK4: structure and function

Cyclin-Dependent Kinase 4 (CDK4) is a critical enzyme that regulates the cell cycle, particularly the progression from the G1 phase to the S phase, where DNA replication occurs. CDK4 is cyclin-dependent kinase 4, which helps to form a complex with cyclin D, which then phosphorylates the retinoblastoma (Rb) protein. This phosphorylation inactivates retinoblastoma (Rb), releasing E2F transcription factors that promote the transcription of genes necessary for DNA synthesis and cell division. 

In liposarcoma, CDK4 is frequently amplified, especially in well-differentiated (WDL) and dedifferentiated (DDL) subtypes, leading to excessive and uncontrolled cell proliferation. This amplification disturbed the normal balance of cell growth and division, contributing to tumour development and progression.

CDK4 amplification is associated with MDM2 amplification, creating a genetic ‘’signature’’ that is characteristic of WDL and DDL. In benign lipomas, these molecular alterations are absent, which makes CDK4 an essential diagnostic biomarker.

It’s detected through immunohistochemistry (IHC) or fluorescence in situ hybridisation (FISH), which helps pathologists accurately distinguish liposarcoma from benign adipocytic tumours, guiding appropriate clinical management and treatment strategies.

Diagnostic techniques

Advanced molecular diagnostic techniques distinguish liposarcoma from benign lipomatous tumours. The following methods are commonly used to detect MDM2 and CDK4 gene amplification or protein overexpression:

• Immunohistochemistry (IHC): In tissue samples, it is a widely used technique that detects the overexpression of MDM2 and CDK4 proteins. It is cost-effective and quick, and provides strong supportive evidence for liposarcoma when both markers are positive
• Fluorescence In Situ Hybridisation (FISH): In this method, it uses fluorescent probes to detect gene amplification of MDM2 and CDK4 in tumour cells. For confirming gene amplification in suspected cases, FISH (Fluorescence In Situ Hybridisation) is considered to be the gold standard
• Comparative Genomic Hybridisation (CGH): This technique identifies imbalances in chromosomes, which are amplifications or deletions across the genome. It helps detect the 12q13-15 amplification region that includes MDM2 and CDK4 in liposarcoma
• RT-PCR and Next-Generation Sequencing (NGS): These methods provide detailed gene expression levels and mutations. NGS (Next-Generation Sequencing )panels can detect a broad range of genomic alterations, offering comprehensive insights into the tumour’s molecular profile

Together, these techniques enhance diagnostic accuracy and support personalised treatment decisions for patients with liposarcoma.

Clinical significance

The use of molecular markers such as MDM2 and CDK4 has important clinical implications in the diagnosis and management of liposarcoma:

Differential diagnosis: lipoma vs. WDL/DDL

In soft tissue tumour pathology most common challenge is distinguishing benign lipomas from well-differentiated liposarcomas (WDL) and dedifferentiated liposarcomas. Histologically, lipomas and liposarcomas are similar, but they are not similar in genetic amplification. IHC or FISH helps to detect MDM2 and CDK4 amplification, serving as reliable markers to make this critical distinction.

Prognosis 

MDM2/CDK4 amplification is not only diagnostic, but it also has prognostic value. WDLs generally have a better treatment outcome, but it can be recurrent, while DDLs are more aggressive and have a higher risk of metastasis. Molecular profiling helps in risk stratification and monitoring for recurrence.

Role in guiding treatment strategies

In confirmed liposarcoma cases, identifying MDM2 and CDK4 amplification can help to support more aggressive surgical planning and closer postoperative follow-up. In addition, understanding the molecular profile opens doors for targeted therapies, particularly in recurrent cases, where CDK4 inhibitors are being explored in clinical trials.

Future directions

The molecular understanding of liposarcoma continues to evolve, offering promising advancements in diagnosis and treatment:

Emerging markers and gene panels

Beyond MDM2 and CDK4, there are new molecular markers and gene signatures involved in detecting liposarcoma pathogenesis. Technologies like next-generation sequencing (NGS) are capable of comprehensive gene panels, which can help in better tumour classification, prognosis, and treatment planning.

Potential for targeted therapies

The discovery of genetic alterations opens the door to different targeted therapies. CDK4 inhibitors are examined in clinical trials for patients with CDK4-amplified liposarcoma. Other targets, such as MDM2 antagonists, are also under observation, potentially offering more effective alternatives to conventional chemotherapy.

Overall, ongoing research into the molecular landscape of liposarcoma holds significant promise for enhancing diagnostic accuracy, expanding treatment options, and advancing individualised patient care.

Summary

Liposarcoma is a malignant tumour of fat tissue, with well-differentiated and dedifferentiated subtypes often showing MDM2 and CDK4 gene amplification. MDM2 and CDK4 molecular markers play a main role in the proper identification of liposarcoma from benign lipomas, which also helps to guide diagnosis, prognosis, and treatment planning. Diagnostic procedures like IHC(Immunohistochemistry), FISH(Fluorescence In Situ Hybridisation), and NGS(Next-Generation Sequencing), these techniques help to detect the disease easily. The combination of molecular profiling not only advances the clinical management but also rectifies targeted therapies and personalised treatment procedures, marking a significant advancement in soft tissue sarcoma care.